狼疮肾炎纵向评估中随机尿蛋白/肌酐比值的可靠性有限
该研究利用美国国立卫生研究院的狼疮肾炎试验数据,对103例患者每月进行随机尿PCR检测、每3个月进行24小时尿PCR检测,最长随访15个月。以24小时PCR趋势线为金标准,发现随机尿PCR仅41%患者可靠,35%不可靠,且不可靠者难以预测、更可能治疗反应差,结论认为随机尿PCR不应常规用于狼疮肾炎管理。
要点
- 随机尿PCR在狼疮肾炎纵向随访中仅41%患者可靠,35%不可靠。
- 随机尿PCR不可靠性无法事前预测,且与治疗反应差相关。
- 随机尿PCR不宜作为狼疮肾炎临床决策依据。
核心结论
- 随机尿PCR在狼疮肾炎纵向评估中可靠性有限,不应常规用于临床管理。
研究设计与样本
- 基于美国国立卫生研究院狼疮肾炎试验数据库,纳入103例患者,每月检测随机尿PCR,每3个月检测24小时尿PCR,随访至多15个月。
主要发现
- 随机尿PCR在41%患者中可靠,24%有问题,35%不可靠。
- 随机尿PCR不可靠的患者无法预先识别,且更可能对治疗反应不佳。
- 随机尿PCR序列常大幅偏离24小时尿PCR趋势线,若用于实时决策可能导致管理错误。
关键数值与推荐
- 以24小时尿PCR趋势线为金标准,结合既往95%置信区间估计,将随机尿PCR分为可靠、有问题或不可靠。
临床怎么用
- 狼疮肾炎纵向管理中应优先采用24小时尿PCR,避免仅凭随机尿PCR调整治疗。
局限性
- 样本来自单一临床试验,结论外推至其他肾小球疾病需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cross-sectional studies document that the spot protein/creatinine ratio (PCR) is often an inaccurate estimate of proteinuria magnitude compared with the 24-hour PCR, which is the gold standard. However, the extent to which the inaccuracy of the spot PCR varies over time and between individuals has not previously been reported. We address these crucial questions using a unique database, an National Institutes of Health trial in which lupus nephritis (LN) patients (N = 103) provided spot PCR testing each month and 24-hour PCR testing every 3 months for up to 15 months after induction therapy. METHODS: A gold standard proteinuria trend line was constructed for each patient by joining the points that represented the serial 24-hour PCR values of the patient. The spot PCR values of the patient were then plotted in relationship to the 24-hour PCR trend line. Using our previous work, which estimated the 95% confidence intervals for the 24-hour PCR at specific levels, we determined in each patient whether the spot PCR values were "reliable," "problematic," or "unreliable." The sequential spot PCR of the patients deviated widely and often from the 24-hour PCR trend line, to the extent that, if the spot PCR results were used in real time for clinical decision-making, it was likely management errors would occur. RESULTS: Spot PCRs were reliable in 41%, problematic in 24%, and unreliable in 35% of patients. Those with unreliable spot PCRs could not be predicted and were more likely to respond poorly to treatment. CONCLUSION: The spot PCR should not be used for management of LN, and perhaps, other glomerulopathies.
引用
- Shidham G, Ayoub I, Birmingham D, et al. Limited Reliability of the Spot Urine Protein/Creatinine Ratio in the Longitudinal Evaluation of Patients With Lupus Nephritis. Kidney Int Rep. 2018. PMID: 30197972. doi:10.1016/j.ekir.2018.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。